Meeting
2023 ASCO Annual Meeting
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).
Presenter
Thomas Stricker
Tennessee Oncology
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6507)
DOI
10.1200/JCO.2023.41.16_suppl.6507
Abstract #
6507
Abstract Disclosures
Similar Videos & Slides
Speaker: Arti Hurria, MD
Videos & Slides
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
Speaker: Richard O'Hara, PhD
Videos & Slides
2023 ASCO Annual Meeting
Sanofi Oncology Pipeline and CEACAM5: A Potential Biomarker in Advanced Non-Small Cell Lung Cancer for Targeted Therapies
Speaker: Phillip Dennis
Videos & Slides
2023 ASCO Annual Meeting
Sanofi Oncology Pipeline and CEACAM5: A Potential Biomarker in Advanced Non-Small Cell Lung Cancer for Targeted Therapies
Speaker: Giovanno Abbadessa